Circulating chromogranin a reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-α-elicited endothelial activation

Journal of Leukocyte Biology

Volumn 85, Issue 1, 2009, Pages 81-87

  Di Comite, Gabriele ^a   Rossi, Carlo M ^a   Marinosci, Alessandro ^a   Lolmede, Karine ^a   Baldissera, Elena ^a   Aiello, Patrizia ^a   Voll, Reinhard E ^d   Rovere Querini, Patrizia ^a   Sabbadini, Maria Grazia ^a   Corti, Angelo ^a,b   Manfredi, Angelo A ^a,e   Mueller, Ruediger B ^c   Herrmann, Martin ^c  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b Research Unit of Molecular Neuroscience   (Italy)

^c Department of Internal Medicine III ^*

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e San Raffaele Scientific University Institute   (Italy)

Author keywords

Arthritis; Cell activation; HMGB1; Inflammation; Neuropeptides

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CHROMOGRANIN A; CORTICOSTEROID; CYCLOSPORIN; GOLD SALT; HIGH MOBILITY GROUP B1 PROTEIN; HYDROXYCHLOROQUINE; INTERCELLULAR ADHESION MOLECULE 1; LEFLUNOMIDE; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PENICILLAMINE; PROTEIN ANTIBODY; RECOMBINANT PROTEIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; CELL STIMULATION; CLINICAL FEATURE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; INFLAMMATION; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; NEUROENDOCRINE SYSTEM; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SJOEGREN SYNDROME; STIMULUS RESPONSE; VASCULITIS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CELLS, CULTURED; CHEMOKINE CCL2; CHROMOGRANIN A; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEEDBACK, BIOCHEMICAL; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MICROVESSELS; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; SEROSITIS; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 58149234057     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0608358     Document Type: Article

References (48)

1. Derijk, R. H., Schaaf, M. J., Turner, G., Datson, N. A., Vreugdenhil, E., Cidlowski, J., de Kloet, E. R., Emery, P., Sternberg, E. M., Detera-Wadleigh, S. D. (2001) A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor Bβ-isoform mRNA is associated with rheumatoid arthritis. J. Rheumatol. 28, 2383-2388.
2. Vassilopoulos, D., Mantzoukis, D. (2006) Dialogue between the brain and the immune system in inflammatory arthritis. Ann. N. Y. Acad. Sci. 1088, 132-138.
3. Sternberg, E. M. (2006) Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 6, 318-328.
4. Di Comite, G., Grazia Sabbadini, M., Corti, A., Rovere-Querini, P., Manfredi, A. A. (2007) Conversation galante: how the immune and the neuroendocrine systems talk to each other. Autoimmun. Rev. 7, 23-29.
5. Di Comite, G., Marinosci, A., Di Matteo, P., Manfredi, A., Rovere-Querini, P., Baldissera, E., Aiello, P., Corti, A., Sabbadini, M. G. (2006) Neuroen-docrine modulation induced by selective blockade of TNF-α in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1069, 428-437.
6. Harle, P., Straub, R. H., Wiest, R., Mayer. A., Scholmerich, J., Atzeni, F., Carrabba. M., Gutolo, M., Sarzi-Puttini, P. (2006) Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary- adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. Ann. Rheum. Dis. 65, 51-56.
7. Capellino, S., Lowin, T., Angele, P., Falk, W., Grifka, J., Straub, R. H. (2008) Increased chromogranin A levels indicate sympathetic hyperactivity in patients with rheumatoid arthritis and systemic lupus erythematosus. J. Rheumatol. 35, 91-99.
8. Tracey, K. J. (2007) Physiology and immunology of the cholinergie anti-inflammatory pathway. J. Clin. Invest. 117, 289-296.
9. Goldstein, R. S., Bruchfeld, A., Yang, L., Qureshi, A. R., Gallowitsch-Puerta, M., Patel, N. B., Huston, B. J., Chavan, S., Rosas-Ballina, M., Gregersen, P. K., Czura, C. J., Sloan, R. P., Sama, A. E., Tracey, K. J. (2007) Cholinergic anti-inflammatory pathway activity and high mobility group box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mot. Med. 13, 210-215.
10. Kokkola, R., Sundberg, E., Ulfgren, A. K., Palmblad, K., Li, J., Wang, H., Ulloa, L., Yang, H., Yan, X. J., Furie, R., Chiorazzi, N., Tracey, K. J., Andersson, U., Harris, H. E. (2002) High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 46, 2598-2603.
11. Taniguchi, N., Kawahara, K., Yone, K., Hashiguchi, T., Yamakuchi, M., Goto, M., Inoue, K., Yamada, S., Ijiri, K., Matsunaga, S., Nakajima. T., Komiya, S., Maruyama, I. (2003) High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 48, 971-981.
12. Andersson, U., Tracey, K. J. (2004) HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic- target in arthritis. Rheum. Dis. Clin. North Am. 30, 627-637.
13. Jiang, W., Pisetsky. D. S. (2007) Mechanisms of disease: the role of high-mobility group protein 1 in the pathogenesis of inflammatory arthritis. Nat. Clin. Pract. Rheumatol. 3, 52-58.
14. Zetterstrom, C. K., Jiang, W., Wahamaa. H., Ostberg, T., Aveberger, A. C., Schierbeck, H., Lotze, M. T., Andersson, U., Pisetsky, D. S., Erlandsson Harris, H. (2008) Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic; effects of gold sodium thiomalate. J. Leukoc. Biol. 83, 31-38.
15. Taupenot, L., Harper, K. L., O'Connor, D. T. (2003) The chromogranin-secretogranin family. N. Engl. J. Med. 348, 1134-1149.
16. Helle, K. B., Gorti, A., Metz-Boutigue, M. H., Tota, B. (2007) The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell. Mol. Life Sci. 64, 2863-2886.
17. Di Comite, G., Previtali, P., Rossi, C. M., Dell'Antonio, G., Rovere-Querini, P., Praderio, L., Dagna, L., Corti, A., Doglioni, C., Maseri, A., Sabbadini, M. G., Manfredi, A. A. (2008) High blood levels of chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment. Ann. Rheum. Dis., in press.
18. Ferrero, E., Scabini, S., Magni, E., Foglieni, C., Belloni, D., Colombo, B., Curnis, F., Villa, A., Ferrero. M. E., Corti. A. (2004) Chromogranin A protects vessels against tumor necrosis factor α-induced vascular leakage. FASEB J. 18, 554-556.
19. Blois, A., Srebro, B., Mandala, M., Corti, A., Helle, K. B., Serck-Hanssen, G. (2006) The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. Regul. Pept. 135, 78-84.
20. Corti, A., Ferrari, R., Ceconi, C. (2000) Chromogranin A and tumor necrosis factor-α (TNF) in chronic heart failure. Adv. Exp. Med. Biol. 482, 351-359.
21. Pieroni, M., Corti, A., Tota, B., Curnis, F., Angelone, T., Colombo, B., Cerra, M. C., Bellocci, F., Crea, F., Maseri, A. (2007) Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur. Heart J. 28, 1117-1127.
22. Schulze, P. C. (2007) Chromogranin A: friend or foe of the failing myocardium? Eur. Heart J. 28, 1052-1053.
23. Rao, F., Wen, G., Gayen, J. R., Das, M., Vaingankar, S. M., Rana, B. K., Mahata, M., Kennedy, B. P., Salem, R. M., Stridsberg, M., Ahel, K., Smith, D. W., Eskin, E., Schork, N. J., Hamilton. B. A., Ziegler, M. G., Mahata, S. K., O'Connor, D. T. (2007) Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 115, 2271-2281.
24. Genta, M. S., Genta, R. M., Gabay, C. (2006) Systemic rheumatoid vasculitis: a review. Semin. Arthritis Rheum. 36, 88-98.
25. Scott, D. L., Steer, S. (2007) The course of established rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 21, 943-967.
26. Young, A., Koduri, G. (2007) Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 21, 907-927.
27. Arnett, F. C., Edworthy. S. M., Block D. A., McShane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315- 324.
28. Turesson, C., O'Fallon, W. M., Crowson, C. S., Gabriel, S. E., Matteson, E. L. (2003) Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann. Rheum. Dis. 62, 722-727.
29. Turesson, C., Weyand, C. M., Matteson, E. L. (2004) Genetics of rheumatoid arthritis: is there a pattern predicting extraarticular manifestations? Arthritis Rheum. 51, 853-863.
30. Ceconi, C., Ferrari, R., Bachetti, T., Opasich, C., Volterrani, M., Colombo, B., Parrinello, G., Corti, A. (2002) Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur. Heart J. 23, 967-974.
31. Corti. A., Sanchez, L. P., Gasparri, A., Curnis, F., Longhi, R., Brandazza, A., Siccardi, A. G., Sidoli, A. (1997) Production and structure characterization of recombinant chromogranin A N-terminal fragments (vasostatins) - evidence of dimer-monomer equilibria. Eur. J. Biochem. 248, 692-699.
32. De Rycke, L., Peene, I., Hoffman, I. E., Kruithof, E., Union, A., Meheus, L., Lebeer, K., Wyns, B., Vincent, C., Mielants, H., Boullart, L., Serre, G., Veys, E. M., De Keyser, F. (2004) Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann. Rheum. Dis. 63, 1587-1593.
33. Lotze, M. T., Zeh, H. J., Rubartelli, A., Sparvero, L. J., Amoscato, A. A., Washburn, N. R., Devera, M. E., Liang, X., Tor, M., Billiar, T. (2007) The graleful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol. Rev. 220, 60-81.
34. Rianchi, M. E., Manfredi, A. A. (2007) High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 220, 35-46.
35. Turesson, C., Jacobsson, L., Bergstrom. U. (1999) Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 38, 668-674.
36. Chung, C. P., Oeser, A., Raggi, P., Gebretsadik, T., Shintani, A. K., Sokka, T., Pincus, T., Avalos, I., Stein, C. M. (2005) Increased coronary -artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 52, 3045-3053.
37. Crowson, C. S., Nicola, P. J., Kremers. H. M., O'Fallon, W. M., Therneau, T. M., Jacobsen, S. J., Roger, V. L., Ballman, K. V., Gabriel, S. E. (2005) How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum. 52, 3039-3044.
38. De Vries-Bouwstra, J. K., Goekoop-Ruiterman, Y. P., Wesoly, J., Hulsmans, H. J., de Craen, A. J., Breedveld, F. C., Dijkmans, B. A., Allaart, C. F., Huizinga, T. W. (2007) Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with rheumatoid arthritis and with joint damage. Ann. Rheum. Dis. 66, 1033-1037.
39. Allantaz, F., Chaussabel, D., Banchereau, J., Pascual, V. (2007) Microarray-based identification of novel biomarkers in IL-1 -mediated diseases. Curr. Opin. Immunol. 19, 623-632.
40. Ridker, P. M., Hennekens, C. H., Roitman-Johnson. B., Stampfer, M. J., Allen, J. (1998) Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351, 88-92.
41. De Lemos, J. A., Morrow, D. A., Sabaline, M. S., Murphy, S. A., Gibson, C. M., Antman, E. M., McCabe, C. H., Cannon, C. P., Braunwald, E. (2003) Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107, 690-695.
42. Tang, W., Pankow, J. S., Carr, J. J., Tracy, R. P., Bielinski, S. J., North, K. E., Hopkins, P. N., Kraja, A. T., Arnett, D. K. (2007) Association of sICAM-1 and MCP-1 with coronary artery calcification in families enriched for coronary heart disease or hypertension: the NHLBI Family Heart Study. BMC Cardiovasc. Disord. 7, 30.
43. Dumitriu, I. E., Baruah, P., Manfredi, A. A., Bianchi, M. E., Rovere-Querini, P. (2005) HMGB1: guiding immunity from within. Trends Immunol. 26, 381-387.
44. Dumitriu, I. E., Baruah, P., Valentinis. B., Voll, R. E., Herrmann, M., Nawroth, P. P., Arnold, B., Bianchi, M. E., Manfredi, A. A., Rovere-Querini, P. (2005) Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174, 7506-7515.
45. Rovere-Querini, P., Capobianco, A., Scaffidi, P., Valentinis, B., Catal-anotti, F., Giazzon, M., Dumitriu, I. E., Muller, S., Iannacone, M., Tra-versari, C., Bianchi, M. E., Manfredi, A A. (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5, 825- 830.
46. Fiuza, C., Bustin, M., Talwar, S., Tropea, M., Gerstenberger, E., Shel-hamer, J. H., Suffredini, A. F. (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101, 2652- 2660.
47. Treutiger, C. J., Mullins, G. E., Johansson, A. S., Rouhiamen, A., Rauvala, H. M., Erlandsson-Harris, H., Andersson, U., Yang. H., Tracey, K. J., Andersson, J., Palmblad, J. E. (2003) High mobility group 1 B-box mediates activation of human endothelium. j. Intern. Med. 254, 375-385.
48. Mullins, G. E., Sunden-Cullberg, J., Johansson, A. S., Rouhiainen, A., Erlandsson-Harris, H., Yang, H., Tracey, K. J., Rauvala, H., Palmblad, J., Andersson, J., Treutiger, C. J. (2004) Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scand. J. Immunol. 60, 566-573.